TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS RECEIVING CDK4/6 INHIBITORS FOR HR+/HER2ADVANCED/METASTATIC BREAST CANCER IN A SINGLE-CENTRE, CANADIAN REAL-WORLD SETTING USING AI-EXTRACTED DATA

被引：0
|
作者：
Moulson, Ruth [1 ]
Feugere, Guillaume [2 ]
Moreira-Lucas, Tracy [2 ]
Dequen, Florence [2 ]
Weiss, Jessica [1 ]
Smith, Janet [3 ]
Brezden-Masley, Christine [3 ]
机构：
[1] Pentavere, Toronto, ON, Canada
[2] Pfizer Canada, Kirkland, PQ, Canada
[3] Mt Sinai Hosp, New York, NY USA
来源：
BREAST | 2023年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO107
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [41] Analysis of factors affecting oncological outcomes in the treatment of HR plus metastatic breast cancer patients using CDK4/6 inhibitors- real world data
    Milosavljevic, N.
    Petronijevic, M.
    Subanovic, E.
    Vujinovic, I.
    Lucic, J.
    Spasic, M.
    Radojevic, M. Zivkovic
    BREAST, 2025, 80
  • [42] CDK4/6-Inhibition in HR+, HER2-advanced breast cancer: First Real-World Data substantiate Efficacy and Tolerability of Palbociclib even in clinical Practice
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (05) : 246 - 246
  • [43] HR+, HER2-Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
    Sammons, Sarah L.
    Topping, Donna L.
    Blackwell, Kimberly L.
    CURRENT CANCER DRUG TARGETS, 2017, 17 (07) : 637 - 649
  • [44] TREATMENT PATTERNS FOLLOWING FIRST LINE CDK4/6 INHIBITOR PROGRESSION IN HR+, HER2-METASTATIC BREAST CANCER
    Behan, E.
    Bansal, A.
    Veenstra, D.
    VALUE IN HEALTH, 2024, 27 (06) : S406 - S406
  • [45] Breast cancer specific quality of life in HR+/HER2-advanced/metastatic breast cancer patients in a real-world setting.
    Wood, Robert
    Mitra, Debanjali
    De Courcy, Jonathan
    Iyer, Shrividya
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
    Cogliati, Viola
    Capici, Serena
    Pepe, Francesca Fulvia
    di Mauro, Pierluigi
    Riva, Francesca
    Cicchiello, Federica
    Maggioni, Claudia
    Cordani, Nicoletta
    Cerrito, Maria Grazia
    Cazzaniga, Marina Elena
    LIFE-BASEL, 2022, 12 (03):
  • [47] Real-world treatment patterns and clinical effectiveness of eribulin in HR+/HER2-metastatic breast cancer patients in the United States
    Mougalian, S. S.
    Zhang, J.
    Kish, J. K.
    Zettler, M. E.
    Feinberg, B. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S72 - S72
  • [48] Treatment patterns and barriers involving the use of CDK4/6 inhibitors for women with HR+, HER2-breast cancer.
    Tolaney, Sara M.
    O'Shaughnessy, Joyce
    Ackbarali, Tariqa
    Crawford, Rebecca
    Carter, Jeffrey D.
    Greene, Laurence
    Sapir, Tamar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [49] Outcomes of male patients with HR+/HER2-advanced breast cancer receiving palbociclib in the real-world POLARIS study
    Blum, Joanne L.
    Dicristo, Caroline
    Gordon, David
    Karuturi, Meghan S.
    Oubre, David
    Jepsen, Erin
    Cuevas, Juan
    Lakhanpal, Shailendra
    Montelongo, Monica Z.
    Zhang, Zhe
    Cappelleri, Joseph C.
    Wang, Yao
    Tripathy, Debu
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (03) : 463 - 475
  • [50] Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study
    Joanne L. Blum
    Caroline DiCristo
    David Gordon
    Meghan S. Karuturi
    David Oubre
    Erin Jepsen
    Juan Cuevas
    Shailendra Lakhanpal
    Monica Z. Montelongo
    Zhe Zhang
    Joseph C. Cappelleri
    Yao Wang
    Debu Tripathy
    Breast Cancer Research and Treatment, 2024, 203 : 463 - 475
12345